In fact, no relevant side effects were documented (in some cases only an increase in perifocal edema) and neoadjuvant therapy with 90Y-DOTAGA-substance P allowed a higher extent of surgical resection of glioblastomas [22,26]. The gene discussed is TAC1; the disease is glioblastoma.